Announced translational data in heavily pretreated relapsed/refractory multiple myeloma patients, which ...
Announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination ...
GOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results for approved second-line checkpoint inhibitor monotherapy 100% of responding patients survived for longer than one year FDA Fast Track Designation and recent regulatory guidance support advancement toward registration and potential expansion into HPV-driven head and neck cancer SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Co
Announced the Company is presenting a trial-in-progress abstract and e-poster discussing the REO 033 ...
Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.
Provides an update on its intellectual property strategy, outlining progress on new method of use patents ...
Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.
Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected
Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest.
Today announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor ...
By David Bautz, PhD NASDAQ: ONCY READ THE FULL ONCY RESEARCH REPORT Business Update Alignment Reached with FDA on Potential Registrational Pathway in CRC On August 18, 2026, Oncolytics Biotech, Inc. (NASDAQ: ONCY) announced it had received written feedback from the FDA regarding the potential expansion of the ongoing REO 033 trial into a pivotal Part B study. REO 033 is a randomized study
This is the newest page. Registered accounts read further back.